{"organizations": [], "uuid": "ddbbc0961f8b9bc4ee973ad72b73e1be6b62be90", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180119.html", "section_title": "Archive News &amp; Video for Friday, 19 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-orphazyme-granted-rare-pediatric-d/brief-orphazyme-granted-rare-pediatric-disease-designation-by-fda-idUSFWN1PD1J7", "country": "US", "domain_rank": 408, "title": "BRIEF-Orphazyme Granted Rare Pediatric Disease Designation By FDA", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.968, "site_type": "news", "published": "2018-01-19T15:27:00.000+02:00", "replies_count": 0, "uuid": "ddbbc0961f8b9bc4ee973ad72b73e1be6b62be90"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-orphazyme-granted-rare-pediatric-d/brief-orphazyme-granted-rare-pediatric-disease-designation-by-fda-idUSFWN1PD1J7", "ord_in_thread": 0, "title": "BRIEF-Orphazyme Granted Rare Pediatric Disease Designation By FDA", "locations": [], "entities": {"persons": [{"name": "arimoclomol", "sentiment": "none"}], "locations": [{"name": "us", "sentiment": "none"}], "organizations": [{"name": "npc", "sentiment": "negative"}, {"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 19 (Reuters) - ORPHAZYME A/S:\n* REG-ARIMOCLOMOL FOR NPC RECEIVES RARE PEDIATRIC DISEASE DESIGNATION\n* ORPHAZYME A/S - ARIMOCLOMOL HAS BEEN GRANTED RARE PEDIATRIC DISEASE DESIGNATION BY US FOOD AND DRUG ADMINISTRATION\n* ORPHAZYME A/S - ARIMOCLOMOL FOR TREATMENT OF NIEMANN-PICK DISEASE TYPE C (NPC). Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-19T15:27:00.000+02:00", "crawled": "2018-01-20T17:34:24.021+02:00", "highlightTitle": ""}